派林生物：关于全资子公司获得药品注册临床试验受理通知书的公告

Group 1 - The core announcement is that the company, through its wholly-owned subsidiary Guangdong Shuanglin Biopharmaceutical Co., Ltd., has received the clinical trial acceptance notice for human thrombin drug registration from the National Medical Products Administration [2] Group 2 - This approval marks a significant step in the company's development of new pharmaceutical products, potentially enhancing its market position in the biopharmaceutical industry [2] - The clinical trial will likely provide valuable data that could lead to future commercialization of the human thrombin drug [2] - The news reflects the company's ongoing commitment to innovation and regulatory compliance in the biopharmaceutical sector [2]